Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis

INTRODUCTION: In 2018, ixekizumab (80 mg every 2 weeks [Q2W] beyond Week 12) received approval in Japan for patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). This open-label study evaluated the efficacy and safety of ixekizumab (80 mg Q2W from Week 12 to Week 20) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Akimichi, Okubo, Yukari, Morisaki, Yoji, Torisu-Itakura, Hitoe, Umezawa, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717693/
https://www.ncbi.nlm.nih.gov/pubmed/34967916
http://dx.doi.org/10.1007/s13555-021-00666-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717693/
https://www.ncbi.nlm.nih.gov/pubmed/34967916
http://dx.doi.org/10.1007/s13555-021-00666-x

Ejemplares similares